Hikma Pharmaceuticals Plc Stock Fundamentals
| HKMPY Stock | USD 49.81 0.70 1.39% |
Hikma Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Hikma Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Hikma Pink Sheet. The fundamental analysis module provides a way to measure Hikma Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hikma Pharmaceuticals pink sheet.
Hikma |
Hikma Pharmaceuticals PLC Company Profit Margin Analysis
Hikma Pharmaceuticals' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Hikma Pharmaceuticals Profit Margin | 0.14 % |
Most of Hikma Pharmaceuticals' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hikma Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Hikma Pharmaceuticals PLC has a Profit Margin of 0.1357%. This is 101.21% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The profit margin for all United States stocks is 110.69% lower than that of the firm.
Hikma Pharmaceuticals PLC Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Hikma Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Hikma Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Hikma Pharmaceuticals competition to find correlations between indicators driving Hikma Pharmaceuticals's intrinsic value. More Info.Hikma Pharmaceuticals PLC is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about 0.50 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Hikma Pharmaceuticals PLC is roughly 2.00 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Hikma Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Hikma Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Hikma Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hikma Pharmaceuticals' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hikma Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Hikma Pharmaceuticals by comparing valuation metrics of similar companies.Hikma Pharmaceuticals is currently under evaluation in profit margin category among its peers.
Hikma Fundamentals
| Return On Equity | 0.15 | |||
| Return On Asset | 0.077 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 5.26 B | |||
| Shares Outstanding | 110.13 M | |||
| Price To Earning | 10.10 X | |||
| Price To Book | 1.89 X | |||
| Price To Sales | 1.60 X | |||
| Revenue | 2.55 B | |||
| Gross Profit | 1.3 B | |||
| EBITDA | 759 M | |||
| Net Income | 421 M | |||
| Cash And Equivalents | 393 M | |||
| Cash Per Share | 3.57 X | |||
| Total Debt | 651 M | |||
| Debt To Equity | 0.71 % | |||
| Current Ratio | 2.12 X | |||
| Book Value Per Share | 19.77 X | |||
| Cash Flow From Operations | 638 M | |||
| Earnings Per Share | 2.99 X | |||
| Price To Earnings To Growth | 2.41 X | |||
| Number Of Employees | 8.7 K | |||
| Beta | 0.35 | |||
| Market Capitalization | 4.72 B | |||
| Total Asset | 4.37 B | |||
| Retained Earnings | 1.16 B | |||
| Working Capital | 701 M | |||
| Current Asset | 1.57 B | |||
| Current Liabilities | 866 M | |||
| Z Score | 4.2 | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 1.79 % | |||
| Net Asset | 4.37 B | |||
| Last Dividend Paid | 0.55 |
About Hikma Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hikma Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hikma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hikma Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company was founded in 1978 and is based in London, the United Kingdom. Hikma Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 8700 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Hikma Pink Sheet Analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.